(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2016 (19.05.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/077498 A1

(51) International Patent Classification:
A61K 38/00 (2006.01) *A61K 38/12* (2006.01)

(21) International Application Number:
PCT/US2015/060222

(22) International Filing Date:
11 November 2015 (11.11.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/078,888 12 November 2014 (12.11.2014) US

(71) Applicant: **LYRIC PHARMACEUTICALS INC.** [US/US]; 601 Gateway Boulevard, Suite 1020, South San Francisco, California 94080 (US).

(72) Inventors: **WURTMAN, David**; 601 Gateway Boulevard, Suite 1020, South San Francisco, California 94080 (US). **JAMES, Joyce**; 601 Gateway Boulevard, Suite 1020, South San Francisco, California 94080 (US). **HARRIS, M. Scott**; 601 Gateway Boulevard, Suite 1020, South San Francisco, California 94080 (US).

(74) Agent: **CONKLIN, David R.**; Kirton McConkie, 50 East South Temple, Salt Lake City, Utah 84111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TREATMENT OF ENTERAL FEEDING INTOLERANCE

(57) Abstract: Enteral Feeding Intolerance (EFI) can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Therapeutic benefit can be obtained from single and consecutive daily dosing, including for periods of up to a week or longer.

Ulimorelin




FIG. 1

WO 2016/077498 A1

Published:

— *with international search report (Art. 21(3))*